|
Release Date
June 17, 2011
|
Expiration Date
June 17, 2012 |
|
|
| Faculty |
James O. Armitage, MD
University of Nebraska
Omaha, Nebraska, United States
|
Andreas Engert, MD
University of Cologne
Cologne, Germany
|
|
Antonio Palumbo, MD
University of Torino
Torino, Italy
|
Luciano Wannesson, MD
Oncology Institute of Southern Switzerland
Bellinzona, Switzerland
|
|
Target Audience
This educational activity is specifically designed for hematologists, oncologists, and other healthcare
professionals involved and/or interested in the management of patients with hematologic malignancies.
|
Overview
These interviews discuss recently released data from the 2011 Malignant Lymphoma Meeting in Lugano focusing on various aspects of the management of patients with hematologic malignancies. |
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- Describe the latest management approaches for hematologic malignancies including lymphoma, chronic lymphocytic leukemia, and multiple myeloma
- Evaluate difficult or unusual problems encountered by the practicing hematologist/oncologist and identify appropriate management options based on emerging data
- Discuss issues surrounding the design and conduct of clinical trials that incorporate novel agents and/or regimens for patients with hematologic malignancies
- Summarize emerging data in the management of multiple hematologic malignancies and integrate new findings into clinical practice
|
Sponsorship
This activity is sponsored by prIME Oncology. |
Continuing Medical Education
prIME Oncology is accredited by the Accreditation Council of Continuing Medical Education (ACCME®) to provide continuing medical education for physicians. |
Credit Designation Statement
prIME Oncology designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Each interview may provide the following credits:
2011542-1: Engert (Hodgkin disease) – 0.25 CME credits
2011542-2: Wannesson (CLL/NHL) – 0.25 CME credits
2011542-3: Palumbo (Myeloma) – 0.5 CME credits
|
Method of Participation
There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this
CME activity will be recorded in prIME Oncology's database. However, upon request, your CME credit certificate will be emailed to you.
Links to the post tests are available on the video player pages.
|
Support Statement
The activity is supported by an educational grant from Celgene Corporation.
|
Disclosure of Conflicts of Interest
prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME Activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Dr Armitage has disclosed that he has received consulting fees from Seattle Genetics; GSK; Eisai; and Ziopharm. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Engert has disclosed that he has received consulting fees from Seattle Genetics; Novartis; and Millennium. He has performed contracted research for Novartis and Millennium. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Palumbo has disclosed that he has received consulting fees from Celgene and Janssen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Wannesson has disclosed that he has received consulting fees from Roche and Boehringer Ingelheim. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
Janelle Bowersox, RN (clinical) – no relevant financial relationships with commercial supporters of this activity
Trudy Stoddert, ELS (editorial) – no relevant financial relationships with commercial supporters of this activity
Heather Tomlinson (editorial) – no relevant financial relationships with commercial supporters of this activity
Susan H Yarbrough, CCMEP (compliance) – no relevant financial relationships with commercial supporters of this activity
|
Disclosure of Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
